HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $37
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $35 to $37.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $35 to $37.